Top 9 Companies in the Inflammatory Bowel Disease Treatment Market in 2024

The inflammatory bowel disease treatment market was valued at USD 19.6 billion in 2023. The market is expected to grow at a CAGR of 5.71% during the forecast period of 2024-2032, with the values likely to reach USD 20.7 billion by 2032. The market is driven by the increasing prevalence of inflammatory bowel disease across the 8 major markets.

Inflammatory bowel disease, such as Crohn's disease and ulcerative colitis, is commonly treated by medicines aimed to decrease inflammation, alleviate symptoms, and bring about remission. Such medicines comprise aminosalicylates, corticosteroids, immunosuppressants, and biologics like TNF inhibitors. In some cases, surgery is necessary where large parts of the intestines must be removed. The treatment plan is often designed according to each patient's specific symptoms and the pattern of disease progression for improvement of quality of life and prevention of complications.

The treatment market for inflammatory bowel disease is rapidly expanding driven by the increasing prevalence of the disease and the introduction of innovative therapeutics. Improvements in biologics and immunotherapy have allowed for much better treatment options, giving patients more effective and optimal control over their diseases and managing their symptoms. The market is further influenced by rising awareness, early diagnosis, and improved patient outcomes.

In October 2023, Teva and Sanofi accelerated their Phase 2b program for anti-TL1A therapy, focusing on severe ulcerative colitis and Crohn’s disease. This development is likely to elevate the market value by introducing innovative treatments addressing critical needs in inflammatory bowel disease management.

Let’s explore the profile of top companies leading the inflammatory bowel disease treatment market in 2024.

1.    Pfizer Inc.

Pfizer is actively involved in inflammatory bowel disease treatment and focuses on next-generation therapies. It works on innovative approaches, including JAK inhibitors and TL1A targeting therapies as inflammatory mediators. Its research focuses on overcoming the limitations of existing biologics, where more effective and targeted approaches can be made beyond traditional therapies. Pfizer is also engaged in exploring the various pathways of the immune system to improve patient outcomes and redefine the standard of care in inflammatory bowel disease management.

2.    GlaxoSmithKline plc.

GlaxoSmithKline (GSK) has strengthened its presence in the market through the development of Chemocentryx's TRAFFICET-EN. This initiative reflects their commitment to advancing novel treatments for conditions like Crohn's disease and ulcerative colitis. By initiating clinical development, GSK aims to offer innovative solutions for patients with chronic conditions, further enhancing its portfolio in the global inflammatory bowel disease treatment market.

3.    Mylan N.V.

Mylan N.V. actively participates in the treatment market for inflammatory bowel diseases through strategic partnerships. The company focuses on developing biologic drugs for potential U.S. Food and Drug Administration (FDA) approval, targeting patients with inflammatory bowel diseases. This initiative highlights Mylan's efforts to strengthen its biopharmaceutical portfolio and commitment to addressing chronic conditions.

4.    Teva Pharmaceutical Industries Ltd.

Teva Pharmaceutical Industries has been a pioneer in advancing the advancement of treatments for inflammatory bowel diseases. Through collaborations and clinical trials, the company has developed innovative therapies that aim to address the growing demand for effective treatments in the market. Novel biologics, such as the anti-TL1A therapy, demonstrate the company's commitment to improving the outcomes for these patients.

5.    Sanofi SA

Sanofi SA is a global leader in healthcare, with an active involvement in the treatment market for inflammatory bowel illnesses. The company focuses on developing innovative therapies for conditions like Crohn's disease and ulcerative colitis. With a strong pipeline and commitment to improving patient outcomes, it seeks to address the growing demand for effective treatments, contributing to the advancements in preventing inflammatory bowel diseases.

6.    Janssen Pharmaceuticals Inc.

Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson, has been an integral part of the global treatment market for inflammatory bowel diseases through its product, Stelara, or ustekinumab. The company has been focusing on improving the patient's outcome with long-term evidence of safety and efficacy, for conditions such as Crohn's disease or ulcerative colitis. Their research and development continue to enhance the general therapeutic aspects of inflammatory bowel disease drugs.

7.    Merck & Co.

Merck is a prominent player in the global inflammatory bowel disease treatment market with its drug, Tulisokibart (MK-7240). This anti-TL1A monoclonal antibody is designed to target key molecules involved in disease progression in inflammatory bowel diseases. Their research emphasizes their commitment to advancing new therapeutic options for inflammatory bowel disease patients.

8.    Eli Lilly and Company

Eli Lilly and Company is advancing inflammatory bowel disease treatment with its investigational drug, mirikizumab, the first and only IL-23p19 antagonist to show successful results in ulcerative colitis therapy. Their contribution to innovative medicine has led to the establishment of solutions to effective treatments for patients with inflammatory bowel diseases.

9.    AbbVie Inc.

AbbVie Inc. has been a major player in the global inflammatory bowel disease treatment market. Through collaborations, they advanced the treatment options available for inflammatory bowel disease, particularly focusing on enhancing patient outcomes. This showcases their commitment to addressing unmet needs in inflammatory bowel disease management with innovative, targeted treatments.